Trials / Completed
CompletedNCT01638858
Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
A Prospective, Non-randomized, Mono-center, Cohort Study of Evaluate the Effects of 0.5mg Intraocular Ranibizumab (Lucentis)Injections on Retinal Function in Patients With Diabetic Macular Edema (DME) During Twelve Months
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- University of Luebeck · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis. Measurements with the multifocal electroretinogram (ERG) and microperimetry is used here as an objective criteria to information about the retinal function obtain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lucentis (Ranibizumab) | Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-07-01
- First posted
- 2012-07-12
- Last updated
- 2014-07-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01638858. Inclusion in this directory is not an endorsement.